PVR INOX

PVR INOX is riding a strong run, with Drishyam 3 contributing about ₹65 crore over its opening weekend, 10-15% ahead of expectations (Fortune India, 6 Oct). Ticket-price caps, metro-heavy premium screens and weak 'A' certificate films limit the gains (Mint, 5 Oct).

What it means

PVR INOX's revenue growth is the hard number; whether its ticket and F&B prices kept up is the open question.

Reported: Revenue +11.9% in Q1 FY27 on a net profit of ₹56.5 cr, against a net loss of ₹54.5 cr a year earlier.

Watch: Q2 FY27 results, expected late Oct — revenue growth below Q1's 11.9%.

Before its next results, expected late Oct:Before then:

Affected
  • Rival multiplexes — a pace to matchDo now: By late Oct: benchmark your growth against this pace.
  • PVR INOX's film distributors and F&B suppliers — orders growing with itDo now: By late Oct: plan its orders on this growth.
PVR INOX moved from a consolidated net loss in Q1 FY26 to a net profit in Q1 FY27

Both figures from 23 Jul 2026 reports.

₹54.5 crore
₹56.5 crore

Latest moves

Our read of each move first, where we have one; what the report said is marked Reported.

All 134 stories on PVR INOX

Footprint: where PVR INOX opened

1 store opening in 1 city on record since May 2026; 2 announced plans.

India store openings tracker →

Background

From 8 stories, the newest dated 7 Oct 2026. Summary written 10 Oct 2026. Newer developments are under Latest moves.

PVR INOX is an Indian multiplex operator that runs around 1,800 screens. [1] source: Business Today

Show 3 more paragraphs and 8 sources

CLSA's rating note puts that at 1,800 of India's 4,000 multiplex screens. [2] source: Moneycontrol The Multiplex Association of India cited a PVRINOX average ticket price of Rs 258 and food and beverage spend of Rs 132 per head in FY2023-24. [3] source: Business Standard

In October 2026, PVR Inox shares rose 9.75% to a 52-week high after CLSA kept its Outperform rating and Investec raised its target to Rs 1,821 from Rs 1,466. [1] source: Business Today The chain is targeting 100 additional screens in FY27 and has identified around 300 tier-three and tier-four cities. [1] source: Business Today Drishyam 3 contributed ₹65 crore at PVR INOX over its opening weekend, 10-15% ahead of expectations, and long-weekend footfall was more than 30 lakhs. [4] source: Fortune India On 26 January 2026, PVR Inox sold its entire 93.27 per cent stake in Zea Maize, owner of the 4700BC snack brand, to Marico for Rs 226.8 crore in cash. [5] source: Business Standard In October 2026, a Hyderabad consumer commission ordered PVR Inox and PVR Cinemas to pay ₹20,000 in compensation and deposit ₹50,000 as punitive damages after ads delayed a film by nearly 22 minutes. [6] source: Business Standard

Cinepolis is the rival named most often alongside PVR INOX. It sold 7.8 lakh tickets overall on the October 2 weekend. [4] source: Fortune India Executives at both chains say regional films are moving into premium formats such as IMAX. [7] source: Mint

Sources

  1. PVR Inox jumps 9.75% to 52-week high as CLSA, Investec cite rising footfalls; 100 screens planned in FY27Business Today

How these pages are builtReport a correction

Questions about PVR INOX

How many PVR INOX stores are there?

PVR INOX runs around 1,800 screens, according to a Business Today report from October 2026. [1] source: Business Today

What is PVR INOX's current strategy in India?

PVR INOX sold its 93.27 per cent stake in Zea Maize to Marico for Rs 226.8 crore on 26 January 2026. [5] source: Business Standard In October 2026 it added post-midnight shows for Drishyam The Conclusion alongside Cinepolis. [8] source: Business Today It is also targeting 100 additional screens in FY27. [1] source: Business Today

Who are PVR INOX's main competitors?

PVR INOX's main named rival is Cinepolis. Cinepolis sold 7.8 lakh tickets overall on the October 2, 2026 weekend, while PVR INOX reported more than 30 lakhs long-weekend footfall. [4] source: Fortune India

More stories about PVR INOX

Stories that mention PVR INOX

3 stories

PVR INOX is named in these stories but is not their subject.